Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep66 | Adrenal and Cardiovascular Endocrinology | ECE2020

Indications for aldosterone/renin screening presented by patients later diagnosed with hyperaldosteronism in a general endocrinology outpatient clinic

Ramos Elvira , Barrio Elvira , Moraga Inmaculada , Cuesta Martin , Pazos Mario , Pallares Raquel , Saez de Parayuelo Victoria , Fernandez Luzdivina , Calle Pascual Alfonso , Runkle Isabel

Introduction: Endocrine Society guideline indications for screening (EGS) of hypertensive patients for hyperaldosteronism are not universally followed in clinical Endocrinology. We present a series of patients with hyperaldosteronism, diagnosed following strict EGS compliance.Methods: Retrospective. Following compliance with EGS in all patients attended in a general Endocrinology outpatient clinic, 70 hypertensive patients were diagnosed with hyperaldost...

ea0056oc10.4 | Cardiovascular aspects of endocrine diseases | ECE2018

Improvement in the control of hypertension in diabetic patients screened for hyperaldosteronism

Jimenez Ines , Crespo Irene , Cuesta Martin , Elvira Carlos , de Miguel Paz , Santiago Alejandro , Fernandez Luzdivina , de Parayuelo Maria Victoria Saez , Calle Alfonso , Runkle Isabelle

Introduction: Control of hypertension (HT) is essential to reduce cardiovascular events in diabetic patients (DPts). However, studies indicate that only 50% of DPts with treated hypertension present adequate blood pressure (BP) control. Yet Endocrine-Society-Guideline (ESG) screening for primary hyperaldosteronism (PHA) is rarely applied. Furthermore, in patients with essential hypertension (EH), longer-acting hypertension medication (HM) improves 24-hour BP when compared to r...

ea0056p754 | Neuroendocrinology | ECE2018

Initiation of tolvaptan therapy for mild/moderate chronic SIADH-induced hyponatremia in a day-ward

Ramos Elvira , Barrio Elvira , Miguel Paz de , Cuesta Martin , Fernandez Luzdivina , Victoria Saez de Parayuelo Maria , Maria Cruz Anba , Ortiz Marta , Calle Alfonso , Runkle Isabelle

Introduction: Tolvaptan is the only V2-receptor antagonist authorized for use in Europe in patients with SIADH. Its initiation requires hospitalization. Our goal was to analyze the safety and efficacy of tolvaptan started in a Hospital Day-Ward.Material and methods: Retrospective descriptive study of 33 ambulatory patients with mild/moderate SIADH-induced chronic sustained hyponatremia initiating tolvaptan therapy in the Day-Ward of a tertiary center ove...